Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | F11 | P03951 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HCK | P08631 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10368097 | 0.77 | CA12 (0.47) | RIPK1HPGDCA12CA9F11 | |
| SCHEMBL10366373 | 0.77 | GRIK1 (0.58) | HPGDCA12CA9F11LMNA | |
| SCHEMBL10366372 | 0.76 | CA12 (0.46) | HPGDCA12CA9F11MAPT | |
| SCHEMBL4290533 | 0.74 | CA12 (0.53) | CA12CA9F11AR | |
| SCHEMBL16573987 | 0.74 | CA12 (0.73) | HPGDCA12CA9F11MAPT | |
| SCHEMBL4553772 | 0.73 | MAPT (0.53) | CA12CA9F11MAPTLMNA | |
| SCHEMBL29374162 | 0.73 | BRPF1 (0.45) | RIPK1HPGDNPSR1MCOLN3CA12 | |
| SCHEMBL4552802 | 0.72 | CA12 (0.57) | HPGDCA12CA9F11POLB | |
| SCHEMBL4553299 | 0.72 | MAPT (0.52) | CA12CA9F11MAPTLMNA | |
| SCHEMBL18713523 | 0.71 | CA12 (0.47) | CA12CA9F11MAPTPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122060893-A | KASP molecular marker associated with erigeron breviscapus ester B and application thereof | 云南农业大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-4720072-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | disclosed |
| US-12576109-B2 | Allogeneic human plasma and platelet derived products and uses thereof | CONSANO BIO, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250302873-A1 | ALLOGENEIC HUMAN PLASMA AND PLATELET DERIVED PRODUCTS AND USES THEREOF | CONSANO BIO, INC. | 2025-10-02 | — | — | US | disclosed |
| WO-2024249299-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20230313189-A1 | COMPLEMENT COMPONENT 4 INHIBITORS FOR TREATING NEUROLOGICAL DISEASES, AND RELATED COMPOSITONS, SYSTEMS AND METHODS OF USING SAME | GENENTECH, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| CN-112736923-B | Natural gas network cascading failure assessment control method considering power grid failure influence | 华南理工大学 | 2023-06-20 | — | — | CN | disclosed |
| US-20230056230-A1 | Therapy for the Treatment of Cancer | MACROGENICS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4081248-A1 | THERAPY FOR THE TREATMENT OF CANCER | MacroGenics, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-114901306-A | Therapy for the treatment of cancer | 宏观基因有限公司 | 2022-08-12 | — | — | CN | disclosed |
| EP-2126053-B1 | APOCRINE CELL LINE | UNILEVER PLC (GB) | 2010-11-17 | — | — | EP | disclosed |
| US-20100184213-A1 | APOCRINE CELL LINE | CONOPCO, INC. D/B/A UNILEVER | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078133-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | RIPK1 2325/4885HPGD 4265/4885NPSR1 3975/4885 |
| US-12576109-B2 | Allogeneic human plasma and platelet derived products and uses thereof | FGB, PDGFRB, PDGFA | RIPK1 3979/4885HPGD 2789/4885NPSR1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.